Tags : Radiation

Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion

Vartika Singh June 7, 2019

Shots: The positive opinion recommendation follows the study assessing arginine and lysine of same content as LysaKare, evaluating its safety and efficacy The EC will review CHMP’s opinion with its […]readmore

Pharma

BMS Report Results of Opdivo + Radiation in P-III CheckMate

Tuba Khan May 10, 2019

Shots: The P-III CheckMate -498 study involves assessing of Opdivo (nivolumab) + radiation vs temozolomide + radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM The P-III CheckMate -498 (NCT02617589) […]readmore

Tags : Radiation

Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion

BMS Report Results of Opdivo + Radiation in P-III CheckMate

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Radiation

Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion

﻿BMS Report Results of Opdivo + Radiation in P-III CheckMate

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

BMS Report Results of Opdivo + Radiation in P-III CheckMate